Title |
Wie soll die Hormontherapie beim kastrationsresistenten Prostatakarzinom fortgeführt werden?
|
---|---|
Published in |
Die Urologie, January 2012
|
DOI | 10.1007/s00120-011-2738-9 |
Pubmed ID | |
Authors |
M. Spahn, M. Krebs |
Abstract |
After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but still androgen-sensitive tumor growth. Our understanding and the treatment of such castration-resistant prostate cancer has changed markedly. The introduction of new drugs like abiraterone and MDV3100 has shown that prostate cancer progression even in the"hormone-refractory" stage is driven by androgen receptor signaling. Based on this information the question of whether androgen deprivation therapy in castration-resistant prostate cancer should be continued or not is still of relevance. This review gives a critical overview of the literature and current guideline recommendations. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 1 | 50% |
Student > Master | 1 | 50% |
Readers by discipline | Count | As % |
---|---|---|
Psychology | 1 | 50% |
Medicine and Dentistry | 1 | 50% |